Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 22;28(1):661-670.
doi: 10.3390/curroncol28010064.

Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature

Lawrence Kasherman  1 , Jeffrey Doi  2 , Katherine Karakasis  1 , Jeffrey Schiff  3 , Abhijat Kitchlu  4 , Stephanie Lheureux  1 , Amit M Oza  1
Affiliations
Review

Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature

Lawrence Kasherman et al. Curr Oncol. .

Abstract

Solid organ transplant recipients on long-term immunosuppressive medication are at increased risk of developing malignancy, and treatment of advanced cancers with angiogenesis inhibitors in this context has not been widely studied. We present a case of recurrent high-grade serous ovarian carcinoma treated with paclitaxel and bevacizumab in the context of prior renal transplantation where the patient responded well to treatment with controlled toxicities, discussing the potential for increased rates of adverse events and drug interactions in this select population.

Keywords: angiogenesis inhibitor; bevacizumab; case report; nephrotoxicity; proteinuria; transplant; vascular endothelial growth factor.

PubMed Disclaimer

Conflict of interest statement

We have read and understood Current Oncology’s policy on disclosing conflicts of interest and declare that we have none.

Figures

Figure 1
Figure 1
Angiogenesis pathways in malignancy and targeted therapies commonly used. Monoclonal antibodies including bevacizumab and ramucirumab and tyrosine kinase inhibitors including sunitinib, sorafenib, lenvatinib, pazopanib, axitinib, cediranib, and cabozantinib have been included (this list is not exhaustive). Receptors including VEGFR, c-kit, epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), and PDGFR are displayed here, but certain medications also target other pathways not displayed here such as AXL and RET. The VEGFR pathway intersects with multiple cell signaling pathways, including the PI3K/AKT/mTOR pathway. Created with Biorender.com.
Figure 2
Figure 2
(a) Summary oncology treatment timeline. (b) Ca125 trend from diagnosis to current.
See this image and copyright information in PMC

References

    1. National Comprehensive Cancer Network Ovarian Cancer (Version 1.2020) [(accessed on 31 August 2020)]; Available online: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.
    1. Gurevich F., Perazella M.A. Renal effects of anti-angiogenesis therapy: Update for the internist. Am. J. Med. 2009;122:322–328. doi: 10.1016/j.amjmed.2008.11.025. - DOI - PubMed
    1. Touyz R.M., Herrmann S.M., Herrmann J. Vascular toxicities with VEGF inhibitor therapies–Focus on hypertension and arterial thrombotic events. J. Am. Soc. Hypertens. 2018;12:409–425. doi: 10.1016/j.jash.2018.03.008. - DOI - PMC - PubMed
    1. Zhang Z.-F., Wang T., Liu L.-H., Guo H.-Q. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis. PLoS ONE. 2014;9:e90135. doi: 10.1371/journal.pone.0090135. - DOI - PMC - PubMed
    1. Wu S., Kim C., Baer L., Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J. Am. Soc. Nephrol. 2010;21:1381–1389. doi: 10.1681/ASN.2010020167. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources